Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million) in the first phase of a Series B1 financing round, led by ZBJL Capital and supported by debt financing. The funds will be used to advance Phase II clinical studies for first-tier products and Phase I clinical trials for some second-tier drug candidates.
Company Overview and Research Focus
Immunophage Bio is a clinical-stage biotech company focused on basic and translational medical research targeting major diseases. The company operates small-molecule and macromolecule screening platforms to develop innovative therapies.
Current Clinical Trials and Pipeline
Immunophage’s MIF inhibitor IPG1094 and CCR8 antagonist IPG7236 are currently undergoing Phase I clinical trials in China, the United States, and Australia. Additionally, its small molecule GPCR antagonist IPG11406, NAD+ inhibitor IPG8294, and CCR8 bifunctional antibody IPG0521 have entered the clinical filing stages.
Significance of the Funding
The Series B1 financing will significantly bolster Immunophage Biotech’s ability to advance its drug development pipeline. This investment underscores the company’s commitment to bringing innovative treatments to market, addressing critical unmet medical needs.-Fineline Info & Tech
